Market Overview:
The global bioengineered protein drugs market is expected to grow at a CAGR of 10.8% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of chronic diseases, rising demand for biologics, and technological advancements in the field of bioengineering. Based on type, the global bioengineered protein drugs market is segmented into monoclonal antibodies, therapeutic proteins, and vaccines. Monoclonal antibodies are expected to account for the largest share of this market in 2018. This segment is projected to grow at a CAGR of 11% during the forecast period from 2018 to 2030. The large share of this segment can be attributed to its high efficacy and growing demand for targeted therapies against cancer and other chronic diseases. Based on application, the global bioengineered protein drugs market is divided into five segments: cancer, diabetes mellitus (DM), autoimmune disorders such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), infectious diseases such as HIV/AIDS and tuberculosis (TB), neurodegenerative disorders such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), and others including cardiovascular diseases (CVDs)and hematological malignancies).
Product Definition:
Bioengineered protein drugs are medications that are produced through biotechnology. This means that the proteins are made in a laboratory, using cells or microorganisms such as bacteria, yeast, or viruses. Bioengineered protein drugs can be used to treat a variety of diseases, including cancer, heart disease and diabetes.
Monoclonal Antibodies:
Monoclonal antibodies are antibody molecules that are manufactured by the human body specifically targeting and binding to a specific target. There are two types of Monoclonal Antibodies, ones produced by the B cell and ones produced by the T cell. The most common type of monoclonal antibody is mAb which stands for monomeric antigen-binding antibody.
Therapeutic Proteins:
Therapeutic proteins are the protein therapeutics that are used to treat incurable diseases such as cancer, Alzheimer's disease, and Parkinson's disease. These drugs act by targeting a diseased or damaged part of the body and repairing or replacing it. The most common forms of therapeutic proteins include monoclonal antibodies (mAbs), recombinant proteins, nanomaterials/biopharmaceuticals, and peptides.
Application Insights:
The application segment is segregated into seven sub-segments, namely cancer, diabetes, autoimmune disorder, infectious disease, neurodegenerative disorders and others. Cancer dominated the overall market in terms of revenue share in 2017. Increasing prevalence of cancer and growing research activities are factors responsible for this large share. According to WHO in 2018 around 1 out of 6 people die from cancer worldwide.
Moreover, bioengineered proteins have shown potential as therapeutic drugs for the treatment of various cancers such as lung cancer (Non-Small Cell Lung Cancer), pancreatic cancer (Pancreatic Carcinoma), liver & biliary tractcancer (Liver & Biliary Tract Cancer) and breast carcinoma (Breast Cervical Carcinoma). In addition to this bioengineered proteins have also been studied for their use in treating skin tumors such as malignant melanomas and keratinizing tumors such as sebostasisand basal cell carcinoma.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of a large number of biopharmaceutical manufacturers, which are engaged in commercializing products based on proteins derived from genetically modified bacteria and yeast. The region is expected to maintain its dominance over the forecast period as well owing to factors such as favorable government regulations and increasing R&D activities related to bioengineered proteins.
Asia Pacific is anticipated to witness lucrative growth during the forecast period owing to rising disposable income, improving healthcare infrastructure, growing awareness about early diagnosis of chronic diseases among people, and high unmet medical needs pertaining cancer, infectious disease & diabetes). These factors are expected contribute toward higher product demand over this period. Moreover it has been observed that countries like China have a significantly high number of patients suffering from cancer; therefore demand for drugs developed through genetic engineering is likely increase in Asia Pacific during this time frame (2018-2030).
Growth Factors:
- Increasing prevalence of chronic diseases: The global prevalence of chronic diseases is increasing at an alarming rate. This is primarily because of the changing lifestyles and dietary habits of people across the world. Bioengineered protein drugs are effective in treating a wide range of chronic diseases, including cancer, diabetes, and heart disease. As a result, their demand is expected to rise significantly in the coming years.
- Technological advancements: The field of bioengineering is constantly evolving, with new technologies being developed every day to improve the efficacy and safety profile of bioengineered protein drugs. This is likely to result in increased adoption rates for these drugs in the coming years.
- Rising healthcare expenditure: Globally, healthcare expenditure is on the rise as more people become aware about the benefits of preventive care measures and treatments for various illnesses and conditions. This has led to an increase in demand for high-quality medical products and services, including bioengineered protein drugs therapies . As a result, this market segment is expected to grow at a healthy rate over the next few years..
Scope Of The Report
Report Attributes
Report Details
Report Title
Bioengineered Protein Drugs Market Research Report
By Type
Monoclonal Antibodies, Therapeutic Proteins, Vaccines
By Application
Cancer, Diabetes, Autoimmune Disorder, Infectious Disease, Neurodegenerative, Others
By Companies
Dr.Reddy’s, Eli Lilly, Merck, Reliance Life Sciences, Panacea Biotech, Novartis, Fresenius, Sanofi, ProBioGen, GlaxoSmithKline, Dr.Reddy’s, Amoytop Biotech, Shanghai United Cell Biotechnology, Hualan Bio
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
171
Number of Tables & Figures
120
Customization Available
Yes, the report can be customized as per your need.
Global Bioengineered Protein Drugs Market Report Segments:
The global Bioengineered Protein Drugs market is segmented on the basis of:
Types
Monoclonal Antibodies, Therapeutic Proteins, Vaccines
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Cancer, Diabetes, Autoimmune Disorder, Infectious Disease, Neurodegenerative, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Dr.Reddy’s
- Eli Lilly
- Merck
- Reliance Life Sciences
- Panacea Biotech
- Novartis
- Fresenius
- Sanofi
- ProBioGen
- GlaxoSmithKline
- Dr.Reddy’s
- Amoytop Biotech
- Shanghai United Cell Biotechnology
- Hualan Bio
Highlights of The Bioengineered Protein Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Monoclonal Antibodies
- Therapeutic Proteins
- Vaccines
- By Application:
- Cancer
- Diabetes
- Autoimmune Disorder
- Infectious Disease
- Neurodegenerative
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Bioengineered Protein Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Bioengineered proteins are proteins that have been modified using genetic engineering techniques. This means that the protein has been altered in some way so that it is no longer naturally occurring. Bioengineered proteins can be used to treat a variety of medical conditions, and they may also have other benefits, such as improved performance in sports or increased strength and durability.
Some of the key players operating in the bioengineered protein drugs market are Dr.Reddy’s, Eli Lilly, Merck, Reliance Life Sciences, Panacea Biotech, Novartis, Fresenius, Sanofi, ProBioGen, GlaxoSmithKline, Dr.Reddy’s, Amoytop Biotech, Shanghai United Cell Biotechnology, Hualan Bio.
The bioengineered protein drugs market is expected to grow at a compound annual growth rate of 10.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Bioengineered Protein Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Bioengineered Protein Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Bioengineered Protein Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Bioengineered Protein Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Bioengineered Protein Drugs Market Size & Forecast, 2020-2028
4.5.1 Bioengineered Protein Drugs Market Size and Y-o-Y Growth
4.5.2 Bioengineered Protein Drugs Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Monoclonal Antibodies
5.2.2 Therapeutic Proteins
5.2.3 Vaccines
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Cancer
6.2.2 Diabetes
6.2.3 Autoimmune Disorder
6.2.4 Infectious Disease
6.2.5 Neurodegenerative
6.2.6 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Bioengineered Protein Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Bioengineered Protein Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Monoclonal Antibodies
9.6.2 Therapeutic Proteins
9.6.3 Vaccines
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Cancer
9.10.2 Diabetes
9.10.3 Autoimmune Disorder
9.10.4 Infectious Disease
9.10.5 Neurodegenerative
9.10.6 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Monoclonal Antibodies
10.6.2 Therapeutic Proteins
10.6.3 Vaccines
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Cancer
10.10.2 Diabetes
10.10.3 Autoimmune Disorder
10.10.4 Infectious Disease
10.10.5 Neurodegenerative
10.10.6 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Monoclonal Antibodies
11.6.2 Therapeutic Proteins
11.6.3 Vaccines
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Cancer
11.10.2 Diabetes
11.10.3 Autoimmune Disorder
11.10.4 Infectious Disease
11.10.5 Neurodegenerative
11.10.6 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Monoclonal Antibodies
12.6.2 Therapeutic Proteins
12.6.3 Vaccines
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Cancer
12.10.2 Diabetes
12.10.3 Autoimmune Disorder
12.10.4 Infectious Disease
12.10.5 Neurodegenerative
12.10.6 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Monoclonal Antibodies
13.6.2 Therapeutic Proteins
13.6.3 Vaccines
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Cancer
13.10.2 Diabetes
13.10.3 Autoimmune Disorder
13.10.4 Infectious Disease
13.10.5 Neurodegenerative
13.10.6 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Bioengineered Protein Drugs Market: Competitive Dashboard
14.2 Global Bioengineered Protein Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Dr.Reddy’s
14.3.2 Eli Lilly
14.3.3 Merck
14.3.4 Reliance Life Sciences
14.3.5 Panacea Biotech
14.3.6 Novartis
14.3.7 Fresenius
14.3.8 Sanofi
14.3.9 ProBioGen
14.3.10 GlaxoSmithKline
14.3.11 Dr.Reddy’s
14.3.12 Amoytop Biotech
14.3.13 Shanghai United Cell Biotechnology
14.3.14 Hualan Bio
